- Home
- LPSN vs LITS Comparison
LPSN vs LITS Comparison
Compare LPSN & LITS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LPSN | LITS |
|---|---|---|
| Founded | 1995 | 2000 |
| Country | United States | United States |
| Employees | N/A | 4 |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.6M | 25.7M |
| IPO Year | 2000 | N/A |
Fundamental Metrics
Financial Performance| Metric | LPSN | LITS |
|---|---|---|
| Price | $1.86 | $0.97 |
| Analyst Decision | Hold | |
| Analyst Count | 1 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 64.2K | ★ 175.7K |
| Earning Date | 05-06-2026 | 05-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $249,838,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.39 | $0.69 |
| 52 Week High | $7.54 | $3.03 |
Technical Indicators
Market Signals| Indicator | LPSN | LITS |
|---|---|---|
| Relative Strength Index (RSI) | 51.63 | 52.52 |
| Support Level | $1.80 | $0.93 |
| Resistance Level | $2.44 | $0.99 |
| Average True Range (ATR) | 0.09 | 0.05 |
| MACD | 0.02 | -0.00 |
| Stochastic Oscillator | 90.22 | 44.06 |
Price Performance
Historical ComparisonAbout LPSN LivePerson Inc.
LivePerson Inc is the enterprise leader in digital customer conversation. The Conversational Cloud, the Companies enterprise-class digital customer conversation platform, is trusted by the brands to accelerate their contact center transformation, orchestrate conversations across all channels, departments, and systems, increase agent productivity, and deliver more personalized, AI-empowered customer experiences. The company has a presence in the United States, Asia-Pacific, Latin America, and Europe.
About LITS Lite Strategy Inc.
Lite Strategy Inc is focused on the clinical development of novel therapies for cancer. The company's portfolio of drug candidates includes voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor and zandelisib, an oral, once-daily, selective PI3K inhibitor. It is a clinical-stage pharmaceutical company committed to the development of novel and differentiated cancer therapies intended to improve outcomes for patients.